Jl Mag Rare-Earth (06680) plans to register and issue non-financial corporate debt financing instruments in the interbank bond market.
Jinli Permanent Magnet (06680) announced that Jiangxi Jinli Permanent Magnet Technology Co., Ltd. (hereinafter referred to as "the Company") held the sixteenth meeting of the fourth board of directors on August 20, 2026, and approved the proposal on the registration and issuance of non-financial corporate debt financing instruments in the interbank bond market.
Jl Mag Rare-Earth (06680) announced that Jiangxi Jl Mag Rare-Earth Technology Co., Ltd. (hereinafter referred to as the "Company") held the sixteenth meeting of the fourth board of directors on August 20, 2026, to review and approve the proposal on "Proposed Registration and Issuance of Non-Financial Corporate Debt Financing Instruments in the Interbank Bond Market." Based on the general authorization for the issuance of domestic and overseas debt financing instruments approved by the annual general meeting of shareholders in 2025, and in conjunction with the company's business development needs, the company intends to adopt a unified registration model and apply to the Bank of China Interbank Market Dealers Association (hereinafter referred to as the "Dealers Association") for the registration and issuance of non-financial corporate debt financing instruments in the interbank bond market not exceeding RMB 300 million (inclusive). The issuance will be carried out in a one-time or phased manner (hereinafter collectively referred to as "this registration and issuance") according to actual funding requirements and market conditions during the validity period of the registration quota.
Related Articles

LINKLOGIS-W (09959) released its interim results, with a net profit attributable to shareholders of 23.936 million yuan, marking a year-on-year turnaround from loss to profit.

LINKLOGIS-W(09959): Zhang Xiao resigned as Joint Company Secretary, Authorized Representative, and Agent for Legal Proceedings.

LUYE PHARMA (02186) is set to launch II phase clinical trials in China for its mRNA vaccine LY01620, intended for the treatment of cervical precancerous lesions and HPV-related tumors.
LINKLOGIS-W (09959) released its interim results, with a net profit attributable to shareholders of 23.936 million yuan, marking a year-on-year turnaround from loss to profit.

LINKLOGIS-W(09959): Zhang Xiao resigned as Joint Company Secretary, Authorized Representative, and Agent for Legal Proceedings.

LUYE PHARMA (02186) is set to launch II phase clinical trials in China for its mRNA vaccine LY01620, intended for the treatment of cervical precancerous lesions and HPV-related tumors.

RECOMMEND





